Finanzen von Mink Therapeutics Inc (INKT)INKTMink Therapeutics Inc

In the context of the broader market, INKT competes directly with industry leaders such as HYFT and ONCY. With a market capitalization of $52.79M, it holds a significant position in the sector. When comparing efficiency, INKT's gross margin of N/A stands against HYFT's 58.58% and ONCY's N/A. Such benchmarking helps identify whether Mink Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported a net loss of $3.1 million in Q2 2026, which is an improvement from previous quarters but still indicates ongoing financial challenges. The current ratio is 1.23, suggesting that the company can cover its short-term liabilities, but the overall financial health remains weak with total equity at -$14.03 million as of Q2 2026.